Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Trials

The aims of the GHSG’s current trials are to further optimize first-line treatment in all stages of Hodgkin lymphoma and to improve therapy for relapsed patients, while minimizing treatment-related adverse effects and maintaining treatment efficacy.

Active trials

First-line treatment

Brief denomination Title Stage Design
HD17 Treatment optimization trial in the first-line treatment of intermediate stage Hodgkin lymphoma; treatment stratification by means of FDG Intermediate stage Phase III, multicenter, randomized
HD16 Treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma; treatment stratification by means of FDG-PET Early stages Phase III, multicenter, randomized
HD18 Treatment optimization trial in the first-line treatment of Hodgkin lymphoma; treatment stratification by means of FDG-PET Advanced stages Phase III, multicenter, randomized
AVD-Rev Determination of dose-limiting toxicities of lenalidomide in combination with adriamycin, vinblastine and dacarbazine in patients aged between 60 and 75 years Intermediate and advanced stages in elderly patients Phase I, multicenter, not randomized

Treatment of relapses

Brief denomination Title Stage Design
AFM13-101 Trial with a new bi-specific antibody (CD16 and CD30) for determination of dose-limiting toxicities Relapse after autologous stem cell transplantation in elderly patients Phase I, multicenter
Ofatumumab Effectiveness of the fully human CD20 antibody, Ofatumumab Relapse in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) Phase II, monocenter, not randomized

Trials in Preparation

Brief denomination Title Stage Design